Join us to hear what we learned from industry leaders
We asked 140 life sciences leaders what drives or derails commercialization today. They cited fragmented data, limited visibility, unclear ownership, and the challenge of keeping pace with AI and market changes. Big pharma and emerging biopharma take different paths, but each offers lessons from which the other can learn.
Join us for a preview of our findings and real-world lessons from our panel of industry experts.
You’ll learn:
Key drivers and roadblocks across commercial functions
How early is “early enough” for launch planning
What large and small companies can learn from each other
Case studies and practical strategies for commercialization success
About this email: You are receiving this message as part of your complimentary newsletter subscription to BioPharma Dive. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. BioPharma Dive is a product of TechTarget, Inc. and its subsidiaries, 275 Grove St. Newton, MA, 02466
